Literature DB >> 21279524

A comparative study of HIV-1 and HTLV-I protease structure and dynamics reveals a conserved residue interaction network.

Pia Rücker1, Anselm H C Horn, Heike Meiselbach, Heinrich Sticht.   

Abstract

The two retroviruses human T-lymphotropic virus type I (HTLV-I) and human immunodeficiency virus type 1 (HIV-1) are the causative agents of severe and fatal diseases including adult T-cell leukemia and the acquired immune deficiency syndrome (AIDS). Both viruses code for a protease that is essential for replication and therefore represents a key target for drugs interfering with viral infection. The retroviral proteases from HIV-1 and HTLV-I share 31% sequence identity and high structural similarities. Yet, their substrate specificities and inhibition profiles differ substantially. In this study, we performed all-atom molecular dynamics (MD) simulations for both enzymes in their ligand-free states and in complex with model substrates in order to compare their dynamic behaviors and enhance our understanding of the correlation between sequence, structure, and dynamics in this protein family. We found extensive similarities in both local and overall protein dynamics, as well as in the energetics of their interactions with model substrates. Interestingly, those residues that are important for strong ligand binding are frequently not conserved in sequence, thereby offering an explanation for the differences in binding specificity. Moreover, we identified an interaction network of contacts between conserved residues that interconnects secondary structure elements and serves as a scaffold for the protein fold. This interaction network is conformationally stable over time and may provide an explanation for the highly similar dynamic behavior of the two retroviral proteases, even in the light of their rather low overall sequence identity.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21279524     DOI: 10.1007/s00894-011-0971-1

Source DB:  PubMed          Journal:  J Mol Model        ISSN: 0948-5023            Impact factor:   1.810


  53 in total

1.  The Protein Data Bank.

Authors:  H M Berman; J Westbrook; Z Feng; G Gilliland; T N Bhat; H Weissig; I N Shindyalov; P E Bourne
Journal:  Nucleic Acids Res       Date:  2000-01-01       Impact factor: 16.971

2.  Comparison of inhibitor binding in HIV-1 protease and in non-viral aspartic proteases: the role of the flap.

Authors:  A Gustchina; I T Weber
Journal:  FEBS Lett       Date:  1990-08-20       Impact factor: 4.124

3.  Studies on the role of the S4 substrate binding site of HIV proteinases.

Authors:  J Tözsér; A Gustchina; I T Weber; I Blaha; E M Wondrak; S Oroszlan
Journal:  FEBS Lett       Date:  1991-02-25       Impact factor: 4.124

4.  Stabilization from autoproteolysis and kinetic characterization of the human T-cell leukemia virus type 1 proteinase.

Authors:  J M Louis; S Oroszlan; J Tözsér
Journal:  J Biol Chem       Date:  1999-03-05       Impact factor: 5.157

5.  Closing of the flaps of HIV-1 protease induced by substrate binding: a model of a flap closing mechanism in retroviral aspartic proteases.

Authors:  Gergely Tóth; Attila Borics
Journal:  Biochemistry       Date:  2006-05-30       Impact factor: 3.162

6.  Ionization states of the catalytic residues in HIV-1 protease.

Authors:  R Smith; I M Brereton; R Y Chai; S B Kent
Journal:  Nat Struct Biol       Date:  1996-11

7.  HTLV-1 and polymyositis in Jamaica.

Authors:  O S Morgan; P Rodgers-Johnson; C Mora; G Char
Journal:  Lancet       Date:  1989-11-18       Impact factor: 79.321

8.  Rapid structural fluctuations of the free HIV protease flaps in solution: relationship to crystal structures and comparison with predictions of dynamics calculations.

Authors:  Darón I Freedberg; Rieko Ishima; Jaison Jacob; Yun-Xing Wang; Irina Kustanovich; John M Louis; Dennis A Torchia
Journal:  Protein Sci       Date:  2002-02       Impact factor: 6.725

9.  Monoclonal integration of human T-cell leukemia provirus in all primary tumors of adult T-cell leukemia suggests causative role of human T-cell leukemia virus in the disease.

Authors:  M Yoshida; M Seiki; K Yamaguchi; K Takatsuki
Journal:  Proc Natl Acad Sci U S A       Date:  1984-04       Impact factor: 11.205

Review 10.  An HTLV-I vaccine: why, how, for whom?

Authors:  G de Thé; R Bomford
Journal:  AIDS Res Hum Retroviruses       Date:  1993-05       Impact factor: 2.205

View more
  4 in total

1.  Small molecule regulation of protein conformation by binding in the Flap of HIV protease.

Authors:  Theresa Tiefenbrunn; Stefano Forli; Michael M Baksh; Max W Chang; Meaghan Happer; Ying-Chuan Lin; Alexander L Perryman; Jin-Kyu Rhee; Bruce E Torbett; Arthur J Olson; John H Elder; M G Finn; C David Stout
Journal:  ACS Chem Biol       Date:  2013-03-29       Impact factor: 5.100

2.  Human T lymphotropic virus type 1 and risk of cardiovascular disease: High-density lipoprotein dysfunction versus serum HDL-C concentrations.

Authors:  Sara Samadi; Samaneh Abolbashari; Zahra Meshkat; Amir Hooshang Mohammadpour; Theodoros Kelesidis; Aida Gholoobi; Mehrane Mehramiz; Mahla Tabadkani; Fatemeh Sadabadi; Razieh Dalirfardouei; Gordon A Ferns; Majid Ghayour-Mobarhan; Amir Avan
Journal:  Biofactors       Date:  2019-01-29       Impact factor: 6.113

3.  Fluorinated derivatives of tetrahydroaltersolanol molecule on COVID-19, HIV, and HTLV protease by DFT and molecular docking approaches.

Authors:  Maliheh Azadparvar; M Kheirabadi; H A Rahnamaye Aliabad
Journal:  J Mol Model       Date:  2022-10-11       Impact factor: 2.172

4.  Cardiovascular risk profile in patients with myelopathy associated with HTLV-1.

Authors:  Fabio Luís Silva do Prado; Renata Prado; Ana Marice Teixeira Ladeia
Journal:  Braz J Infect Dis       Date:  2017-03-07       Impact factor: 3.257

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.